tweetindex
ES

Gil Morgan, MD ✓

@weoncologists · San Antonio, TX · joined 13 May 2009

Clinical Oncologist from Texas🇺🇸Director of @OncoAlert 🚨 Proudly NIH, NCI & MDA trained. An ounce of prevention equals a pound of cure. Views are own🌏

16 435Followers
7 265Following
34 249Posts total
4.8KViews on collected posts

Últimas publicaciones

The 1st Line Reset and the New Sequencing Problem — what do we want to achieve in HER2+ metastatic #BreastCancer? For the COMPLETE @OncoAlert 🚨HORIZONS VIDEO: https://t.co/eVrSunyHwy 🧑‍⚕️ Session Faculty: Dr. Javier Cortes @JavierCortesMD 🇪🇸 — International Breast Cancer 767 views · 8 likes · 4 reposts · 0 replies Open on X →
Presenting OncoAlert Horizons | Focus: Breast Cancer Educational Series 🚨 In this session, we explore: The 1st Line Reset and the New Sequencing Problem — what do we want to achieve in HER2+ metastatic #BreastCancer? For the COMPLETE VIDEO: https://t.co/8kLNLCu7aT 🧑‍⚕️ Session
2:38
2.1K views · 20 likes · 12 reposts · 0 replies Open on X →
Belgrade 🇷🇸 energy this weekend: 100+ young oncologists from Bulgaria, Croatia, Montenegro, Slovenia and Serbia at NEXTGEN Breast Academy. Huge thanks to AstraZeneca Balkans for the kind invite and to our friend Dr. Miloš Ičević, for co chairing a great session — this next http
595 views · 12 likes · 8 reposts · 0 replies Open on X →
The FDA 🇺🇸 recently granted Breakthrough Therapy Designation to Revolution Medicines' RASONQUE (daraxonrasib) combined with gemcitabine/nab-paclitaxel for treatment-naïve metastatic pancreatic adenocarcinoma, based on encouraging Phase 1/2 RMC-GI-102 data. @OncoAlert 🚨 616 views · 3 likes · 1 reposts · 0 replies Open on X →
TAISHAN-302 : In a phase 3 randomized trial of 451 patients with relapsed small-cell lung #SCLC 🫁 cancer after platinum-based therapy, tambotatug pelitecan significantly improved 📈 outcomes versus topotecan. Just out on NEJM and presented at #WCLC26 🇰🇷 #lungCancer 729 views · 4 likes · 3 reposts · 0 replies Open on X →
A pleasure to publish this at @CD_AACR w/some AMAZING @OncoAlert 🚨colleagues/friends SoMe has immense potential in ALL areas of medicine⚕️ ☑️raises awareness on trials ☑️promotes cancer prevention ☑️amplifies oncology info ☑️enables diverse viewpoints https://t.co/CoLlKTV25f h
0 views · 259 likes · 96 reposts · 16 replies Open on X →

Frente a cuentas del mismo tamaño

5 publicaciones de los últimos 90 días, junto al rango de 10K–100K seguidores. justo en la mediana de su rango de seguidores.

Visualizaciones medianas729esta cuenta924mediana de 10K–100K
Alcance, %4.44%esta cuenta3.62%mediana de 10K–100K
Interacción, %1.56%esta cuenta1.52%mediana de 10K–100K
MétricaEsta cuentaMediana de 10K–100KProporción
Visualizaciones medianas por publicación7299240.79×
Alcance (visualizaciones ÷ seguidores)4.44%3.62%1.23×
Tasa de interacción1.56%1.52%1.02×

Otras cuentas de este rango →   Comparar con otra cuenta →   Cómo se construyen estas referencias →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

72914 Sep
61615 Sep
595
2.1K
767

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.96%14 Sep
0.65%15 Sep
3.36%
1.56%
1.56%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes61.8%47 in total
Reposts36.8%28 in total
Quotes1.3%1 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Cuentas similares